Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 9/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696136 | 0.98 | GNAO1 (0.50) | GNAO1GNAI3GNAI1KCNH2BCHE | |
| SCHEMBL25468135 | 0.95 | GNAO1 (0.41) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL21106038 | 0.89 | SIGMAR1 (0.36) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL25883013 | 0.89 | DRD2 (0.36) | GNAO1GNAI3GNAI1 | |
| SCHEMBL25922528 | 0.88 | GNAO1 (0.47) | GNAO1GNAI3GNAI1KCNH2BCHE | |
| SCHEMBL22861682 | 0.88 | GBA1 (0.36) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL21106034 | 0.86 | GNAO1 (0.34) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL21106931 | 0.84 | GNAO1 (0.53) | GNAO1GNAI3GNAI1KCNH2BCHE | |
| SCHEMBL24765677 | 0.83 | GNAO1 (0.43) | GNAO1GNAI3GNAI1KCNH2BCHE | |
| SCHEMBL23696396 | 0.82 | GRIN2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | GNAO1 4620/4885GNAI3 4707/4885GNAI1 4764/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | GNAO1 1327/4885GNAI3 2283/4885GNAI1 1527/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.